Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
KANSAS CITY, Kan. and BOSTON, March 20, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing innovative prescription medications for cats and dogs (companion animals), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
Stifel and Lazard Capital Markets will act as book-running managers for the offering. William Blair, JMP Securities, and Craig-Hallum Capital Group will act as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; or from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor, New York, NY 10020, or by calling (800) 542-0970.
SOURCE Aratana Therapeutics
More by this Source
Aratana Therapeutics to Participate in Upcoming Investor Events
Dec 11, 2013, 16:03 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.